In particular, immune checkpoint inhibitors (ICIs) by anti-programmed death receptor-1/programmed death-ligand 1 (PD-1/PD-L1) antibodies for high microsatellite instability (MSI-H) and high tumor mutation burden (TMB-H) tumors are effective in multiple studies [91,92,93,94]. The gene discussed is CD274; the disease is neoplasm.